Company news
Minerva Neurosciences, Inc news in 2025
Minerva Neurosciences, Inc's news releases, calls and decks from 2025, newest first.
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
November 19, 2025
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
November 5, 2025
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia through a Phase 3 Confirmatory Trial
October 22, 2025
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
October 21, 2025
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Prepara...
October 20, 2025
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
August 14, 2025
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
May 13, 2025
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
February 25, 2025
Calls in 2025
Decks in 2025
- Q3 2025 Earnings Presentation
Earnings · 15 slides · Nov 6, 2025